This site is intended for health professionals only

New combination diabetes treatment


Takeda Pharmaceuticals has announced that pioglitazone is now licensed for use in combination with insulin in type 2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: